Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 781 AL 795

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers E, Feaster T, Sethuraman G, Sundell K, Skljarevski V, Cline EN, Zhang H, Jerecic J, Honig LS, Salloway S, Sperling R, Trame MN, Dodds MG, Johnson K.

J Prev Alzheimers Dis. 2025 Jan;12(1):100005. doi: 10.1016/j.tjpad.2024.100005. Epub 2025 Jan 1.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis

Jeong SY, Suh CH, Lim JS, Shim WH, Heo H, Choi Y, Kim HS, Kim SJ, Lee JH.

Neurology. 2025 Apr 22;104(8):e213483. doi: 10.1212/WNL.0000000000213483. Epub 2025 Mar 19.

Efficacy of Add-On Agomelatine on Agitation, Aggression, and Neuroprotection in Alzheimer's Disease: A Randomized, Blinded, Controlled Trial

Kargar A, Fetratjoo DH, Moattar R, Tarki A, Golsokhan A, Pouyan N, Amjadi-Goojgi Z, Mostafaei H, Kakeri F, Zendehbad AS, Lima BS, Esmaily H, Noroozian M.

Am J Geriatr Psychiatry. 2025 Aug;33(8):819-834. doi: 10.1016/j.jagp.2025.03.001. Epub 2025 Mar 20.

Diagnostic journey and management of patients with mild cognitive impairment and Alzheimer's disease dementia: A multinational, real-world survey

Vasileva-Metodiev SZ, Spargo D, Klein EG, Quevenco FC, Cotton S, Sanchez-Juan P, Niimi Y, Fowler NR.

J Alzheimers Dis. 2025 Apr;104(4):1212-1234. doi: 10.1177/13872877251322978. Epub 2025 Mar 20.

Zinc Therapy in Mild Cognitive Impairment: Cognitive Stabilization in Pharmacodynamically Responsive Patients in the ZINCAiD Trial

Squitti R, Benussi A, Fostinelli S, Geviti A, Rivolta J, Ventriglia M, Micera A, Rongioletti M, Ghidoni R, Santilli M, Granzotto A, Albanese A, Binetti G, Sensi SL, Borroni B.

Biomolecules. 2025 Sep 1;15(9):1268. doi: 10.3390/biom15091268.

Effectiveness of Individual Cognitive Stimulation on Cognition in Mild Alzheimer's Disease: A Multicenter RCT

Justo-Henriques SI, Lemos R, Rahmatpour P, Silva RCG, Carvalho JO, Ribeiro O.

Psychogeriatrics. 2025 Nov;25(6):e70109. doi: 10.1111/psyg.70109.

High definition transcranial direct current stimulation as an intervention for cognitive deficits in Alzheimer's dementia: A randomized controlled trial

LoBue C, Chiang HS, Salter A, McClintock S, Nguyen TP, Logan R, Smernoff E, Pandya S, Hart J.

J Prev Alzheimers Dis. 2025 Feb;12(2):100023. doi: 10.1016/j.tjpad.2024.100023. Epub 2025 Jan 1.

A meta-analysis and systematic review of interventions to prevent or treat cognitive decline related to Alzheimer's disease in adults with Down syndrome

Munn EE, Montelongo A, Patel VK, Fodstad JC, Ciccarelli MR, Ptomey LT, Pangelinan MM.

Alzheimers Dement. 2025 Jul;21(7):e70471. doi: 10.1002/alz.70471.

The effect of tablet-based multimodal training on cognitive functioning in Alzheimer's disease: A randomized controlled trial

Zuschnegg J, Ropele S, Opriessnig P, Schmidt R, Russegger S, Fellner M, Leitner M, Spat S, Garcia ML, Strobl B, Ploder K, Pszeida M, Hofmarcher-Holzhacker MM, Stoegerer-Oberschmid E, Guttmann-Lattmanig A, Paletta L, Schüssler S, Koini M.

PLoS One. 2025 Aug 13;20(8):e0329931. doi: 10.1371/journal.pone.0329931. eCollection 2025.

Sativex (nabiximols) for the treatment of Agitation & Aggression in Alzheimer's dementia in UK nursing homes: a randomised, double-blind, placebo-controlled feasibility trial

Albertyn CP, Guu TW, Chu P, Creese B, Young A, Velayudhan L, Bhattacharyya S, Jafari H, Kaur S, Kandangwa P, Carter B, Aarsland D.

Age Ageing. 2025 May 31;54(6):afaf149. doi: 10.1093/ageing/afaf149.

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease

Stroud J, Cummings JL, Chumki SR, Such P, Wang D, Palma AM, Zhang Z, Brubaker M, Grossberg GT.

Curr Med Res Opin. 2025 Aug;41(8):1523-1534. doi: 10.1080/03007995.2025.2552278. Epub 2025 Sep 5.

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M.

Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.

Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms

Bayo Jimenez MT, Rivas-García L, Sánchez-González C, Grosso G, Lipari V, Vera-Ramírez L, Battino M, Giampieri F, Quiles JL, Forbes-Hernández TY.

Int J Mol Sci. 2025 Oct 31;26(21):10631. doi: 10.3390/ijms262110631.

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial

Shah A, Estilo A, Sheridan PL, Kalu U, Chen D, Chang D, Slomkowski M, Lee D, Hefting N, Hobart M, Behl S, Such P, Brubaker M, Grossberg GT.

CNS Drugs. 2025 Oct;39(10):1011-1023. doi: 10.1007/s40263-025-01200-9. Epub 2025 Jul 19.

Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial

Kutzsche J, Cosma NC, Kauselmann G, Fenski F, Bieniek C, Bujnicki T, Pils M, Bannach O, Willbold D, Peters O.

Nat Commun. 2025 May 6;16(1):4180. doi: 10.1038/s41467-025-59295-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias